BriLife - Revision history

Prab at 19:12, 16 March 2025

2025-03-16T19:12:03Z

← Older revision		Revision as of 19:12, 16 March 2025
Line 32:		Line 32:
	[[Category:Investigational drugs]]		[[Category:Investigational drugs]]
	{{pharmacology-stub}}		{{pharmacology-stub}}
	~~{{No image}}~~
	<gallery>		<gallery>
	File:Reuven_Rivlin_with_the_first_vaccinator_in_Phase_B_of_the_Israeli_Vaccine_of_the_Israeli_Biological_Institute,_January_2021_(GPOABG_4084).jpg\|Reuven Rivlin with the first vaccinator in Phase B of the Israeli Vaccine of the Israeli Biological Institute, January 2021		File:Reuven_Rivlin_with_the_first_vaccinator_in_Phase_B_of_the_Israeli_Vaccine_of_the_Israeli_Biological_Institute,_January_2021_(GPOABG_4084).jpg\|Reuven Rivlin with the first vaccinator in Phase B of the Israeli Vaccine of the Israeli Biological Institute, January 2021
	</gallery>		</gallery>

Prab: CSV import

2025-02-17T02:07:53Z

CSV import

← Older revision		Revision as of 02:07, 17 February 2025
Line 33:		Line 33:
	{{pharmacology-stub}}		{{pharmacology-stub}}
	{{No image}}		{{No image}}
			<gallery>
			File:Reuven_Rivlin_with_the_first_vaccinator_in_Phase_B_of_the_Israeli_Vaccine_of_the_Israeli_Biological_Institute,_January_2021_(GPOABG_4084).jpg\|Reuven Rivlin with the first vaccinator in Phase B of the Israeli Vaccine of the Israeli Biological Institute, January 2021
			</gallery>

Prab: CSV import

2025-02-10T08:20:44Z

CSV import

← Older revision		Revision as of 08:20, 10 February 2025
Line 32:		Line 32:
	[[Category:Investigational drugs]]		[[Category:Investigational drugs]]
	{{pharmacology-stub}}		{{pharmacology-stub}}
			{{No image}}

Prab: CSV import

2024-03-08T13:54:20Z

CSV import

New page

'''BriLife''' is an [[Investigational vaccine|investigational vaccine]] developed by the [[Israel Institute for Biological Research]] (IIBR) for the prevention of [[COVID-19]]. The vaccine is currently in the clinical trial phase and is not yet approved for general use.

== Overview ==

BriLife is a [[Vesicular stomatitis virus]] (VSV)-based vaccine. The VSV vector has been genetically modified to express the [[Spike protein|spike protein]] of the [[SARS-CoV-2]] virus, which causes COVID-19. The vaccine is designed to stimulate an immune response to this protein, thereby providing immunity to the virus.

== Development and Testing ==

The development of BriLife began in early 2020, shortly after the SARS-CoV-2 virus was identified. The IIBR conducted preclinical testing on animals before moving on to human trials.

The [[Phase I clinical trial|Phase I clinical trial]] for BriLife began in November 2020, with 80 volunteers between the ages of 18 and 55. The [[Phase II clinical trial|Phase II trial]] began in December 2020, with 1,000 volunteers. The [[Phase III clinical trial|Phase III trial]] is expected to involve 30,000 volunteers and will determine the vaccine's efficacy and safety.

== Potential Advantages and Disadvantages ==

One potential advantage of BriLife is that it does not require ultra-cold storage, unlike some other COVID-19 vaccines. This could make it easier to distribute, particularly in regions where cold storage is a challenge.

However, as with any investigational vaccine, there are potential risks. The safety and efficacy of BriLife have not yet been fully established, and it is possible that the vaccine could have side effects or not provide complete protection against COVID-19.

== See Also ==

* [[COVID-19 vaccine]]
* [[COVID-19 pandemic]]
* [[Vaccine trial]]
* [[Israel Institute for Biological Research]]

== References ==

<references />

[[Category:COVID-19 pandemic]]
[[Category:Vaccines]]
[[Category:Investigational drugs]]
{{pharmacology-stub}}